Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.

Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.

Veure altres versions (1)

Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period...

Descripció completa

Dades bibliogràfiques
Autors principals:	Kari Hemminki, Asta Försti, Akseli Hemminki, Börje Ljungberg, Otto Hemminki
Format:	Article
Idioma:	English
Publicat:	Public Library of Science (PLoS) 2022-01-01
Col·lecció:	PLoS ONE
Accés en línia:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0261124&type=printable

Ítems similars

Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years
per: Kari Hemminki, et al.
Publicat: (2022-01-01)

Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
per: Kari Hemminki, et al.
Publicat: (2021-01-01)

Survival in colon and rectal cancers in Finland and Sweden through 50 years
per: Akseli Hemminki, et al.
Publicat: (2021-10-01)

Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor
per: Kari Hemminki, et al.
Publicat: (2021-05-01)

Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment
per: Kari Hemminki, et al.
Publicat: (2022-04-01)

Incidence and survival in laryngeal and lung cancers in Finland and Sweden through a half century.
per: Anni Koskinen, et al.
Publicat: (2022-01-01)

Bladder and upper urinary tract cancers as first and second primary cancers
per: Guoqiao Zheng, et al.
Publicat: (2021-12-01)

Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis
per: Kari Hemminki, et al.
Publicat: (2024-04-01)

Survival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries
per: Filip Tichanek, et al.
Publicat: (2023-01-01)

Survival in gastric and esophageal cancers in the Nordic countries through a half century
per: Kari Hemminki, et al.
Publicat: (2023-05-01)

Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries
per: Kari Hemminki, et al.
Publicat: (2022-12-01)

Conditional survival in breast cancer up to 10 years in the Nordic countries
per: Frantisek Zitricky, et al.
Publicat: (2023-09-01)

Survival trends in hematological malignancies in the Nordic countries through 50 years
per: Kari Hemminki, et al.
Publicat: (2022-11-01)

Survival improvements in esophageal and gastric cancers in the Nordic countries favor younger patients
per: Kari Hemminki, et al.
Publicat: (2024-08-01)

High familial risks in some rare cancers may pinpoint to hidden germline genetics: focus on esophageal, stomach, small intestinal, testis, thyroid and bone cancers
per: Kari Hemminki, et al.
Publicat: (2025-02-01)

Survival in oral and pharyngeal cancers is catching up with laryngeal cancer in the NORDIC countries through a half century
per: Frantisek Zitricky, et al.
Publicat: (2024-01-01)

Age-specific familial risks in cancer as clues to germline genetic and environmental causes: focus on colorectal, endometrial, prostate, kidney, breast and lung cancers
per: Kari Hemminki, et al.
Publicat: (2025-02-01)

Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
per: Kari Hemminki, et al.
Publicat: (2021-08-01)

Incidence and survival in non-hereditary amyloidosis in Sweden
per: Hemminki Kari, et al.
Publicat: (2012-11-01)

Familial risks in and between stone diseases: sialolithiasis, urolithiasis and cholelithiasis in the population of Sweden
per: Kari Hemminki, et al.
Publicat: (2018-07-01)

Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
per: Guoqiao Zheng, et al.
Publicat: (2020-11-01)

Epidemiology of Amyloidosis and Genetic Pathways to Diagnosis and Typing
per: Kari Hemminki, et al.
Publicat: (2021-07-01)

Family history of any cancer for childhood leukemia patients in Sweden
per: Xinjun Li, et al.
Publicat: (2021-08-01)

Survival in Thyroid Cancer in Sweden From 1999 To 2018
per: Zitricky F, et al.
Publicat: (2024-10-01)

Second cancers and causes of death in patients with testicular cancer in Sweden.
per: Luyao Zhang, et al.
Publicat: (2019-01-01)

Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer
per: Riihimäki Matias, et al.
Publicat: (2013-01-01)

Prostate cancer survivors: Risk and mortality in second primary cancers
per: Subhayan Chattopadhyay, et al.
Publicat: (2018-11-01)

Surveillance Bias in Cancer Risk After Unrelated Medical Conditions: Example Urolithiasis
per: Kari Hemminki, et al.
Publicat: (2017-08-01)

Survival in Lung Cancer in the Nordic Countries Through A Half Century
per: Tichanek F, et al.
Publicat: (2023-05-01)

Survival in common cancers defined by risk and survival of family members
per: Jianguang Ji, et al.
Publicat: (2011-10-01)

Familial risks between Graves disease and Hashimoto thyroiditis and other autoimmune diseases in the population of Sweden
per: Hauke Thomsen, et al.
Publicat: (2020-01-01)

Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
per: Guoqiao Zheng, et al.
Publicat: (2021-02-01)

Familial Associations of Colorectal Cancer with Other Cancers
per: Hongyao Yu, et al.
Publicat: (2017-07-01)

Oncolytic viruses for cancer immunotherapy
per: Otto Hemminki, et al.
Publicat: (2020-06-01)

The 'common disease-common variant' hypothesis and familial risks.
per: Kari Hemminki, et al.
Publicat: (2008-01-01)

Oncolytic Immunotherapy: Where Are We Clinically?
per: Akseli Hemminki
Publicat: (2014-01-01)

Portrait of a Leader in Immunotherapeutics<subtitle>Oncolytic viruses for treatment of cancer</subtitle>
per: Akseli Hemminki
Publicat: (2012-08-01)

TILT Biotherapeutics
per: Akseli Hemminki
Publicat: (2017-05-01)

Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
per: Otto Hemminki, et al.
Publicat: (2020-12-01)

Are population level familial risks and germline genetics meeting each other?
per: Kari Hemminki, et al.
Publicat: (2023-03-01)